Cargando…

Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM

Apelin, identified as the endogenous ligand of APJ, exerts various cardiovascular effects. However, the molecular mechanism underlying the regulation of apelin expression in vascular cells is poorly described. Pioglitazone (PIO) and Krüppel-like factor 4 (KLF4) exhibit specific biological functions...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Zhang, Ruonan, Shen, Hailin, Kong, Jing, Lv, Xinrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928522/
https://www.ncbi.nlm.nih.gov/pubmed/31829402
http://dx.doi.org/10.1042/BSR20190317
_version_ 1783482496898301952
author Wang, Ying
Zhang, Ruonan
Shen, Hailin
Kong, Jing
Lv, Xinrui
author_facet Wang, Ying
Zhang, Ruonan
Shen, Hailin
Kong, Jing
Lv, Xinrui
author_sort Wang, Ying
collection PubMed
description Apelin, identified as the endogenous ligand of APJ, exerts various cardiovascular effects. However, the molecular mechanism underlying the regulation of apelin expression in vascular cells is poorly described. Pioglitazone (PIO) and Krüppel-like factor 4 (KLF4) exhibit specific biological functions on vascular physiology and pathophysiology by regulating differentiation- and proliferation-related genes. The present study aimed to investigate the roles of PIO and KLF4 in the transcriptional regulation of apelin in a high-fat diet/streptozotocin rat model of diabetes and in PIO-stimulated vascular smooth muscle cells (VSMCs). Immunohistochemistry, qRT-PCR, and Western blotting assays revealed that the aorta of the Type 2 diabetes mellitus (T2DM) rat models had a high expression of apelin, PIO could decrease the expression of apelin in the PIO-treated rats. In vitro, Western blotting assays and immunofluorescent staining results showed that the basal expression of apelin was decreased but that of KLF4 was increased when VSMCs were stimulated by PIO treatment. Luciferase and chromatin immunoprecipitation assay results suggested that KLF4 bound to the GKLF-binding site of the apelin promoter and negatively regulated the transcription activity of apelin in VSMCs under PIO stimulation. Furthermore, qRT-PCR and Western blotting assay results showed that the overexpression of KLF4 markedly decreased the basal expression of apelin, but the knockdown of KLF4 restored the PIO-induced expression of apelin. In conclusion, PIO inhibited the expression of apelin in T2DM rat models to prevent diabetic macroangiopathy, and negatively regulated the gene transcription of apelin by promoting transcription of KLF4 in the apelin promoter.
format Online
Article
Text
id pubmed-6928522
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-69285222020-01-02 Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM Wang, Ying Zhang, Ruonan Shen, Hailin Kong, Jing Lv, Xinrui Biosci Rep Cardiovascular System & Vascular Biology Apelin, identified as the endogenous ligand of APJ, exerts various cardiovascular effects. However, the molecular mechanism underlying the regulation of apelin expression in vascular cells is poorly described. Pioglitazone (PIO) and Krüppel-like factor 4 (KLF4) exhibit specific biological functions on vascular physiology and pathophysiology by regulating differentiation- and proliferation-related genes. The present study aimed to investigate the roles of PIO and KLF4 in the transcriptional regulation of apelin in a high-fat diet/streptozotocin rat model of diabetes and in PIO-stimulated vascular smooth muscle cells (VSMCs). Immunohistochemistry, qRT-PCR, and Western blotting assays revealed that the aorta of the Type 2 diabetes mellitus (T2DM) rat models had a high expression of apelin, PIO could decrease the expression of apelin in the PIO-treated rats. In vitro, Western blotting assays and immunofluorescent staining results showed that the basal expression of apelin was decreased but that of KLF4 was increased when VSMCs were stimulated by PIO treatment. Luciferase and chromatin immunoprecipitation assay results suggested that KLF4 bound to the GKLF-binding site of the apelin promoter and negatively regulated the transcription activity of apelin in VSMCs under PIO stimulation. Furthermore, qRT-PCR and Western blotting assay results showed that the overexpression of KLF4 markedly decreased the basal expression of apelin, but the knockdown of KLF4 restored the PIO-induced expression of apelin. In conclusion, PIO inhibited the expression of apelin in T2DM rat models to prevent diabetic macroangiopathy, and negatively regulated the gene transcription of apelin by promoting transcription of KLF4 in the apelin promoter. Portland Press Ltd. 2019-12-24 /pmc/articles/PMC6928522/ /pubmed/31829402 http://dx.doi.org/10.1042/BSR20190317 Text en © 2019 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
spellingShingle Cardiovascular System & Vascular Biology
Wang, Ying
Zhang, Ruonan
Shen, Hailin
Kong, Jing
Lv, Xinrui
Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM
title Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM
title_full Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM
title_fullStr Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM
title_full_unstemmed Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM
title_short Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM
title_sort pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting klf4 expression in rat models of t2dm
topic Cardiovascular System & Vascular Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928522/
https://www.ncbi.nlm.nih.gov/pubmed/31829402
http://dx.doi.org/10.1042/BSR20190317
work_keys_str_mv AT wangying pioglitazoneprotectsbloodvesselsthroughinhibitionoftheapelinsignalingpathwaybypromotingklf4expressioninratmodelsoft2dm
AT zhangruonan pioglitazoneprotectsbloodvesselsthroughinhibitionoftheapelinsignalingpathwaybypromotingklf4expressioninratmodelsoft2dm
AT shenhailin pioglitazoneprotectsbloodvesselsthroughinhibitionoftheapelinsignalingpathwaybypromotingklf4expressioninratmodelsoft2dm
AT kongjing pioglitazoneprotectsbloodvesselsthroughinhibitionoftheapelinsignalingpathwaybypromotingklf4expressioninratmodelsoft2dm
AT lvxinrui pioglitazoneprotectsbloodvesselsthroughinhibitionoftheapelinsignalingpathwaybypromotingklf4expressioninratmodelsoft2dm